NEO - NeoGenomics Inc Stock Price, Fair Value and News

14.29USD+0.44 (+3.18%)Delayed as of 26 Apr 2024, 01:01 pm ET

Market Summary

USD14.29+0.44

Delayedas of 26 Apr 2024, 01:01 pm

3.18%

NEO Stock Price

View Fullscreen

NEO RSI Chart

NEO Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-20.09

Price/Sales (Trailing)

2.99

EV/EBITDA

-38.29

Price/Free Cashflow

-57.56

NEO Price/Sales (Trailing)

NEO Profitability

EBT Margin

-16.41%

Return on Equity

-9.34%

Return on Assets

-5.23%

Free Cashflow Yield

-1.74%

NEO Fundamentals

NEO Revenue

Revenue (TTM)

591.6M

Rev. Growth (Yr)

12.15%

Rev. Growth (Qtr)

2.37%

NEO Earnings

Earnings (TTM)

-88.0M

Earnings Growth (Yr)

36.85%

Earnings Growth (Qtr)

22.63%

Breaking Down NEO Revenue

52 Week Range

14.33

(Low)(High)

Last 7 days

0.6%

Last 30 days

-8.6%

Last 90 days

-11.3%

Trailing 12 Months

-3.8%

How does NEO drawdown profile look like?

NEO Financial Health

Current Ratio

6.2

Debt/Equity

0.57

Debt/Cashflow

NEO Investor Care

Shares Dilution (1Y)

0.55%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	529.8M	551.6M	574.8M	591.6M
2022	486.0M	489.3M	496.8M	509.7M
2021	454.0M	488.7M	484.6M	484.3M
2020	419.3M	404.5M	425.3M	444.4M
2019	308.9M	342.9M	378.4M	408.8M
2018	246.2M	251.7M	261.7M	276.7M
2017	241.8M	240.9M	239.3M	240.3M
2016	136.5M	175.2M	210.9M	244.1M
2015	91.9M	95.6M	97.5M	99.8M
2014	69.0M	74.1M	80.4M	87.1M
2013	60.4M	60.4M	63.0M	66.5M
2012	49.8M	55.0M	57.9M	59.9M
2011	36.6M	38.9M	41.2M	43.5M
2010	0	0	0	34.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeoGenomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	tetrault lynn a.	sold	-97,578	15.9651	-6,112	-
Feb 15, 2024	olivo alicia c	sold	-38,712	14.9644	-2,587	general counsel
Jan 01, 2024	harris melody	sold (taxes)	-	-	-7,123	president, enterprise ops
Dec 07, 2023	sherman jeffrey scott	sold (taxes)	-	-	-8,147	chief financial officer
Dec 01, 2023	stone warren	sold (taxes)	-	-	-5,431	president, clinical services
Nov 17, 2023	olivo alicia c	sold	-49,082	18.39	-2,669	general counsel
Sep 30, 2023	olivo alicia c	sold (taxes)	-	-	-14.00	general counsel
Sep 01, 2023	olivo alicia c	sold (taxes)	-	-	-1,666	general counsel
Aug 01, 2023	olivo alicia c	sold (taxes)	-	-	-14.00	general counsel
Jun 01, 2023	sikri vishal	sold (taxes)	-	-	-21,406	president advanced diagnostics

Which funds bought or sold NEO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	IAG Wealth Partners, LLC	unchanged	-	-46.00	1,572	-%
Apr 24, 2024	BROWN ADVISORY INC	added	0.27	-4,024,570	152,009,000	0.20%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	reduced	-67.86	-358,228	162,671	-%
Apr 24, 2024	OAK FAMILY ADVISORS, LLC	added	7.66	74,473	1,692,120	0.65%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-1.1	-40,352	991,932	0.02%
Apr 23, 2024	AMALGAMATED BANK	reduced	-16.18	-145,000	637,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	117	7,939	-%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-1.48	-2,244	50,163	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	261,287	1,089,590	0.01%
Apr 19, 2024	State of Alaska, Department of Revenue	reduced	-0.93	-48,000	1,220,000	0.01%

Are Funds Buying or Selling NEO?

Are funds buying NEO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NEO

No. of Funds

Unveiling NeoGenomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	5.0%	6,382,515	SC 13G
Feb 13, 2024	vanguard group inc	11.12%	14,169,665	SC 13G/A
Feb 09, 2024	brown advisory inc	0.1%	9,536,307	SC 13G/A
Jan 22, 2024	blackrock inc.	15.7%	19,980,993	SC 13G/A
Feb 10, 2023	artisan partners limited partnership	0.0%	10	SC 13G/A
Feb 09, 2023	brown advisory inc	5%	6,337,008	SC 13G
Feb 09, 2023	vanguard group inc	10.83%	13,674,745	SC 13G/A
Feb 06, 2023	wellington management group llp	0.00%	0	SC 13G/A
Jan 23, 2023	blackrock inc.	17.4%	21,932,623	SC 13G/A
Feb 04, 2022	artisan partners limited partnership	6.3%	7,732,355	SC 13G

Recent SEC filings of NeoGenomics Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	8-K	Current Report
Apr 08, 2024	ARS	ARS
Apr 08, 2024	DEF 14A	DEF 14A
Apr 08, 2024	DEFA14A	DEFA14A
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to NeoGenomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-1.06%	5.74%	39.62	7.35	-8.94%	-35.72%
IDXX	40.7B	3.7B	-7.78%	1.64%	48.11	11.11	8.72%	24.44%
A	39.9B	6.7B	-5.63%	2.37%	32.31	5.93	-2.81%	-6.58%
DGX	14.3B	9.3B	5.09%	-7.77%	16.85	1.54	-3.29%	6.68%
CRL	11.7B	4.1B	-14.22%	21.75%	24.63	2.83	3.86%	-2.39%
MEDP	11.5B	2.0B	-3.34%	90.90%	36.88	5.87	25.57%	21.62%
NTRA	11.0B	1.1B	1.43%	83.42%	-25.35	10.18	31.99%	20.63%
EXAS	10.7B	2.5B	-9.89%	-6.21%	-52.28	4.27	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-20.13%	-28.78%	1.7K	2.79	28.93%	111.61%
GH	2.1B	563.9M	-3.00%	-18.05%	-4.36	3.7	25.45%	26.76%
SMALL-CAP
CDNA	391.4M	280.3M	-21.00%	-3.08%	-2.06	1.4	-12.89%	-148.37%
APDN	84.9M	9.0M	1036.36%	409.16%	-11.75	9.44	-53.31%	2.21%
ACRS	84.4M	31.2M	0.85%	-86.61%	-0.95	2.7	5.03%	-1.81%
AWH	40.5M	9.2M	-6.00%	-31.46%	-2.42	4.42	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

NeoGenomics Inc News

Latest updates

NeoGenomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.4%	155,552,000	151,954,000	146,917,000	137,220,000	138,705,000	128,782,000	125,072,000	117,169,000	125,732,000	121,340,000	121,724,000	115,533,000	125,997,000	125,444,000	86,977,000	106,030,000	106,868,000	104,672,000	101,713,000	95,577,000	76,475,000
Gross Profit	8.5%	67,588,000	62,311,000	59,891,000	54,814,000	56,825,000	48,893,000	43,946,000	38,232,000	45,257,000	47,239,000	52,990,000	41,574,000	57,453,000	54,065,000	28,006,000	46,369,000	49,923,000	50,832,000	48,966,000	47,115,000	37,111,000
Operating Expenses	-0.4%	86,162,000	86,506,000	89,785,000	89,887,000	83,208,000	88,403,000	83,648,000	90,260,000	86,824,000	86,952,000	75,357,000	56,681,000	51,914,000	49,396,000	46,913,000	51,662,000	47,602,000	47,173,000	44,488,000	44,567,000	34,289,500
S&GA Expenses	2.6%	18,072,000	17,610,000	18,901,000	16,259,000	17,142,000	16,809,000	17,071,000	16,299,000	15,917,000	15,704,000	17,224,000	13,749,000	13,105,000	11,304,000	10,195,000	13,258,000	12,302,000	11,508,000	12,324,000	11,216,000	8,047,000
R&D Expenses	34.9%	7,127,000	5,285,000	7,502,000	7,395,000	6,675,000	7,312,000	8,626,000	7,713,000	8,513,000	7,409,000	3,495,000	2,456,000	2,100,000	1,964,000	2,105,000	2,060,000	2,080,000	2,611,000	2,587,000	1,209,000	526,000
EBITDA Margin	26.1%	-0.09	-0.12	-0.16	-0.19	-0.24	-0.29	-0.26	-0.03	0.04	0.15	0.20	0.01	-	-	-	-	-	-	-	-	-
Interest Expenses	532.1%	12,271,000	-2,840,000	-2,524,000	1,467,000	6,516,000	139,000	926,000	-1,301,000	4,845,000	1,296,000	902,000	1,177,000	2,194,000	2,458,000	1,548,000	819,000	380,000	203,000	1,304,000	1,826,000	1,464,000
Income Taxes	67.3%	-960,000	-2,935,000	-2,309,000	-2,925,000	-2,837,000	-2,772,000	-5,730,000	-3,753,000	-2,445,000	-2,822,000	-2,437,000	976,000	-7,850,000	-335,000	-11,132,000	1,089,000	-3,861,000	1,348,000	175,000	-2,023,000	1,049,000
Earnings Before Taxes	28.7%	-15,286,000	-21,451,000	-26,640,000	-33,720,000	-25,524,000	-39,624,000	-41,033,000	-53,161,000	-44,203,500	-23,170,000	73,436,000	-21,138,000	7,567,000	2,222,000	-17,956,000	-5,889,000	2,435,000	3,491,000	2,166,000	-4,447,000	1,402,000
EBT Margin	12.1%	-0.16	-0.19	-0.23	-0.26	-0.31	-0.36	-0.33	-0.10	-0.03	0.08	0.13	-0.06	-	-	-	-	-	-	-	-	-
Net Income	22.6%	-14,326,000	-18,516,000	-24,331,000	-30,795,000	-22,687,000	-36,852,000	-35,303,000	-49,408,000	-41,758,500	-20,348,000	75,873,000	-22,114,000	15,417,000	2,557,000	-6,824,000	-6,978,000	6,296,000	2,143,000	1,991,000	-2,424,000	353,000
Net Income Margin	11.3%	-0.15	-0.17	-0.21	-0.24	-0.28	-0.33	-0.30	-0.07	-0.02	0.10	0.15	-0.02	-	-	-	-	-	-	-	-	-
Free Cashflow	209.8%	10,727,000	-9,771,000	-9,042,000	-22,619,000	-8,219,000	-24,116,000	-27,290,000	-37,259,000	-31,763,000	-22,744,000	-22,737,000	-13,621,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.2%	1,681	1,678	1,695	1,709	1,740	1,756	1,792	1,830	1,870	1,906	1,896	1,494	1,227	959	945	732	710	711	697	533	505
Current Assets	1.7%	597	587	585	585	605	603	622	651	682	710	722	943	449	422	419	215	291	292	276	116	104
Cash Equivalents	11.8%	342	306	289	276	263	266	284	306	317	341	369	612	251	233	295	86.00	173	179	167	13.00	10.00
Inventory	0.4%	24.00	24.00	25.00	24.00	24.00	24.00	22.00	24.00	23.00	22.00	21.00	21.00	30.00	21.00	22.00	20.00	14.00	13.00	9.00	10.00	9.00
Net PPE	-2.7%	92.00	95.00	100	103	102	107	111	109	109	107	112	94.00	86.00	85.00	84.00	83.00	64.00	62.00	59.00	61.00	61.00
Goodwill	0%	523	523	523	523	523	523	527	527	527	526	267	45.00	211	211	211	211	199	199	196	196	198
Liabilities	1.2%	740	731	739	735	742	743	749	755	762	769	748	651	294	293	291	227	202	214	207	209	185
Current Liabilities	3.6%	96.00	93.00	95.00	87.00	90.00	85.00	83.00	82.00	87.00	93.00	99.00	68.00	73.00	65.00	62.00	68.00	64.00	69.00	59.00	73.00	61.00
Long Term Debt	0.1%	538	537	537	536	535	535	534	533	532	532	531	530	168	166	165	-	-	-	-	-	-
LT Debt, Non Current	0.1%	538	537	537	536	535	535	534	533	532	532	531	530	168	166	165	-	-	-	-	-	-
Shareholder's Equity	-0.6%	942	947	956	974	998	1,013	1,044	1,075	1,108	1,137	1,148	844	694	666	654	505	507	497	490	324	320
Retained Earnings	-6.2%	-247	-232	-214	-189	-159	-136	-99.55	-64.24	-14.84	27.00	47.00	-28.60	-7.18	-22.60	-25.16	-18.33	-11.36	-17.65	-51.69	-53.68	-19.36
Additional Paid-In Capital	0.7%	1,190	1,182	1,173	1,167	1,161	1,154	1,147	1,142	1,124	1,111	1,101	872	701	689	679	526	520	517	543	379	340
Accumulated Depreciation	2.2%	158	155	147	139	132	125	123	116	110	112	105	99.00	93.00	86.00	80.00	74.00	69.00	64.00	59.00	55.00	50.00
Shares Outstanding	-0.3%	127	127	127	127	127	124	124	124	120	119	118	116	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,400	-	-	-	755	-	-	-	4,100	-	-	-	2,800	-	-	-	1,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	423.5%	17,784	-5,497	-1,548	-12,692	-3,685	-16,272	-16,996	-29,040	-19,776	-7,767	-1,390	2,210	5,985	526	1,882	-6,933	3,359	18,634	-4,721	6,097	15,453
Share Based Compensation	-2.6%	6,990	7,180	5,705	4,758	4,663	4,280	3,626	12,103	10,062	5,237	4,506	2,653	2,676	2,715	2,635	2,186	2,273	3,275	2,313	2,139	1,807
Cashflow From Investing	-17.4%	17,195	20,821	14,949	23,742	-1,063	-4,198	-6,274	12,052	-9,583	-14,686	-453,410	-154,688	-28,854	-70,716	-18,163	-41,708	-6,076	-7,316	-3,042	-3,196	-128,596
Cashflow From Financing	-31.0%	1,270	1,841	64.00	1,379	1,802	2,959	1,011	6,057	2,460	-6,720	204,610	524,935	8,265	4,115	222,600	617	-3,158	137	162,004	483	4,547

NEO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net revenue:
Total net revenue	$ 591,643	$ 509,728	$ 484,329
COST OF REVENUE	347,039	321,832	297,269
GROSS PROFIT	244,604	187,896	187,060
Operating expenses:
General and administrative	243,101	243,356	221,347
Research and development	27,309	30,326	21,873
Sales and marketing	70,842	67,321	62,594
Restructuring charges	11,088	4,516	0
Total operating expenses	352,340	345,519	305,814
LOSS FROM OPERATIONS	(107,736)	(157,623)	(118,754)
Interest income	(16,902)	(6,075)	(3,138)
Interest expense	6,907	7,581	8,220
Other expense (income), net	(644)	213	499
Gain on investment in and loan receivable from non-consolidated affiliate, net	0	0	(109,260)
Loss before taxes	(97,097)	(159,342)	(15,075)
Income tax benefit	(9,129)	(15,092)	(6,728)
NET LOSS	$ (87,968)	$ (144,250)	$ (8,347)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (0.70)	$ (1.16)	$ (0.07)
Diluted (in dollars per share)	$ (0.70)	$ (1.16)	$ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	125,502	124,217	119,962
Diluted (in shares)	125,502	124,217	119,962
Clinical Services
Net revenue:
Total net revenue	$ 495,636	$ 418,754	$ 404,172
COST OF REVENUE	287,059	261,742	244,360
GROSS PROFIT	208,577	157,012	159,812
Advanced Diagnostics
Net revenue:
Total net revenue	96,007	90,974	80,157
COST OF REVENUE	59,980	60,090	52,909
GROSS PROFIT	$ 36,027	$ 30,884	$ 27,248

NEO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 342,488	$ 263,180
Marketable securities, at fair value	72,715	174,809
Accounts receivable, net	131,227	119,711
Inventories	24,156	24,277
Prepaid assets	17,987	15,237
Other current assets	8,239	8,077
Total current assets	596,812	605,291
Property and equipment (net of accumulated depreciation of $158,211 and $131,930, respectively)	92,012	102,499
Operating lease right-of-use assets	91,769	96,109
Intangible assets, net	373,128	408,260
Goodwill	522,766	522,766
Other assets	4,742	5,109
Total non-current assets	1,084,417	1,134,743
Total assets	1,681,229	1,740,034
Current liabilities
Accounts payable	20,334	20,510
Accrued compensation	53,161	40,141
Accrued expenses and other liabilities	15,069	15,070
Current portion of equipment financing obligations	0	70
Current portion of operating lease liabilities	5,610	6,584
Contract liabilities	2,130	7,557
Total current liabilities	96,304	89,932
Long-term liabilities
Convertible senior notes, net	538,198	535,322
Operating lease liabilities	67,871	68,952
Deferred income tax liabilities, net	24,285	34,750
Other long-term liabilities	13,034	13,055
Total long-term liabilities	643,388	652,079
Total liabilities	739,692	742,011
Commitments and contingencies (Note 15)
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,369,142 and 126,913,992 shares issued and outstanding, respectively)	127	127
Additional paid-in capital	1,190,139	1,160,882
Accumulated other comprehensive loss	(1,674)	(3,899)
Accumulated deficit	(247,055)	(159,087)
Total stockholders’ equity	941,537	998,023
Total liabilities and stockholders’ equity	$ 1,681,229	$ 1,740,034

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

CEO	Mr. Christopher Michael Smith BSc
WEBSITE	neogenomics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	2100

NeoGenomics Inc Frequently Asked Questions

What is the ticker symbol for NeoGenomics Inc? What does NEO stand for in stocks?

NEO is the stock ticker symbol of NeoGenomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeoGenomics Inc (NEO)?

As of Thu Apr 25 2024, market cap of NeoGenomics Inc is 1.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEO stock?

You can check NEO's fair value in chart for subscribers.

What is the fair value of NEO stock?

You can check NEO's fair value in chart for subscribers. The fair value of NeoGenomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeoGenomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeoGenomics Inc a good stock to buy?

The fair value guage provides a quick view whether NEO is over valued or under valued. Whether NeoGenomics Inc is cheap or expensive depends on the assumptions which impact NeoGenomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEO.

What is NeoGenomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, NEO's PE ratio (Price to Earnings) is -20.09 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeoGenomics Inc's stock?

In the past 10 years, NeoGenomics Inc has provided 0.152 (multiply by 100 for percentage) rate of return.